The European Union’s medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen’s Alzheimer’s drug, Leqembi, after concluding a safety review. The European ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on ...

TOKYO, Feb 28, 2025 - (JCN Newswire) - NEC Corporation (NEC; TSE: 6701) has developed vRAN that supports the interfaces and components newly specified by the O-RAN Alliance for enhancing the security ...

Eisai plans to lay off 121 employees in the U.S. A former deputy director of China's drug agency is under investigation by anti-corruption authorities. Pfizer has formed a clinical trial ...

Eisai Co., Ltd. has entered into a license agreement granting the exclusive development and distribution rights for the fibroblast growth factor (FGF) receptor selective tyrosine kinase inhibitor ...

NEW YORK – SciClone Pharmaceuticals has licensed exclusive rights to develop and distribute Eisai's FGFR selective tyrosine kinase inhibitor Tasfygo (tasurgratinib) in greater China. Tokyo-based Eisai ...

Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese drugmaker is reworking parts of its operations in the U.S. Eisai plans to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Greece’s Port of Thessaloniki (ThPA S.A.) has become the first port in the EU and the Mediterranean to integrate RightShip’s Maritime Emissions Portal (MEP) under the METAVASEA maritime ...

Sinn Féin MEP Lynn Boylan has said the European Union was "completely blindsided" after she was detained yesterday upon entry to Israel. Ms Boylan is Chair of the EU Palestine Delegation and was ...